Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rautenberg

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Arztliche Fortbildung|January 1, 1994
[The kidney and hypertension]J Scholze, B Rautenberg
Deutsche Medizinische Wochenschrift (1946)|November 8, 2002
[Pitfalls in hypertension management--misjudgements in diagnosis and therapy]J Scholze, B Rautenberg, A Hansen
Zeitschrift Fur Arztliche Fortbildung|April 27, 1992
[Antihypertensive combination therapy with ACE inhibitors]J Scholze, I Pahl, B Rautenberg, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|April 26, 2016
[Case Report on Treatment of Metastatic Breast Cancer with Trastuzumab during Pregnancy]R Rasenack, N Gaupp, B Rautenberg, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 6, 2016
The impact of chemotherapy for breast cancer on sexual function and health-related quality of lifeJuliane Farthmann, A Hanjalic-Beck, J Veit, et al.
ESMO Open|June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA studyM Schmidt, M Thill, J Rey, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyS Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]S Loibl, M Untch, N Burchardi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Arztliche Fortbildung|January 1, 1994
[The kidney and hypertension]J Scholze, B Rautenberg
Deutsche Medizinische Wochenschrift (1946)|November 8, 2002
[Pitfalls in hypertension management--misjudgements in diagnosis and therapy]J Scholze, B Rautenberg, A Hansen
Zeitschrift Fur Arztliche Fortbildung|April 27, 1992
[Antihypertensive combination therapy with ACE inhibitors]J Scholze, I Pahl, B Rautenberg, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|April 26, 2016
[Case Report on Treatment of Metastatic Breast Cancer with Trastuzumab during Pregnancy]R Rasenack, N Gaupp, B Rautenberg, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 6, 2016
The impact of chemotherapy for breast cancer on sexual function and health-related quality of lifeJuliane Farthmann, A Hanjalic-Beck, J Veit, et al.
ESMO Open|June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA studyM Schmidt, M Thill, J Rey, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyS Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]S Loibl, M Untch, N Burchardi, et al.
Pageof 1